MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
4.890
+0.340
+7.47%
After Hours: 4.890 0 0.00% 16:10 11/06 EST
OPEN
4.600
PREV CLOSE
4.550
HIGH
4.910
LOW
4.535
VOLUME
486.48K
TURNOVER
--
52 WEEK HIGH
16.45
52 WEEK LOW
4.109
MARKET CAP
190.40M
P/E (TTM)
-1.2730
1D
5D
1M
3M
1Y
5Y
1D
Entrada Therapeutics price target lowered to $10 from $11 at Roth Capital
TipRanks · 3d ago
Entrada Therapeutics Q3 EPS $(0.94) Beats $(1.01) Estimate, Sales $905.000K Miss $5.871M Estimate
Benzinga · 3d ago
Entrada Therapeutics GAAP EPS of -$0.94 beats by $0.07, revenue of $0.90M misses by $4.97M
Seeking Alpha · 3d ago
Entrada Therapeutics reports Q3 EPS (94c), consensus (99c)
TipRanks · 3d ago
Weekly Report: what happened at TRDA last week (1026-1030)?
Weekly Report · 6d ago
Weekly Report: what happened at TRDA last week (1019-1023)?
Weekly Report · 10/26 09:15
Entrada Therapeutics appoints Linea Aspesi as chief people officer
TipRanks · 10/21 11:05
Press Release: Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
Dow Jones · 10/21 11:00
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.